Medical Oncology Department, H. U. Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Cantabria, Spain.
Medical Oncology Department, Institut Català d'Oncologia-L'Hospitalet del Llobregat, Barcelona, Spain.
Clin Transl Oncol. 2024 Nov;26(11):2800-2811. doi: 10.1007/s12094-024-03568-4. Epub 2024 Jun 24.
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.
肝细胞癌（HCC）是肝脏最常见的原发性恶性肿瘤，也是全球癌症相关死亡的第三大原因。对于有发生 HCC 风险的个体，应提供腹部超声监测。准确的诊断、分期和肝功能对于确定最佳治疗方法至关重要。BCLC 分期系统在西方国家得到广泛认可。管理这种病理需要多学科、个性化的方法，通常采用多模式策略。手术仍然是唯一的治愈方法，尽管局部和系统治疗在手术不适合时也可能提高生存率。在晚期疾病中，对于 ECOG/PS 0-1 和 Child-Pugh 分级 A 的患者应提供全身治疗。
